Related references
Note: Only part of the references are listed.Huntingtin Lowering Strategies for Disease Modification in Huntington's Disease (vol 101, pg 801, 2019)
Sarah J. Tabrizi et al.
NEURON (2019)
Targeting Huntingtin Expression in Patients with Huntington's Disease
Sarah J. Tabrizi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Recent advances in molecular therapies for neurological disease: triplet repeat disorders
Pedro Gonzalez-Alegre
HUMAN MOLECULAR GENETICS (2019)
Antisense oligonucleotides extend survival of prion-infected mice
Gregory J. Raymond et al.
JCI INSIGHT (2019)
Antisense oligonucleotides: the next frontier for treatment of neurological disorders
Carlo Rinaldi et al.
NATURE REVIEWS NEUROLOGY (2018)
Huntingtin suppression restores cognitive function in a mouse model of Huntington's disease
Amber L. Southwell et al.
SCIENCE TRANSLATIONAL MEDICINE (2018)
Therapeutic reduction of ataxin-2 extends lifespan and reduces pathology in TDP-43 mice
Lindsay A. Becker et al.
NATURE (2017)
Control of phosphorothioate stereochemistry substantially increases the efficacy of antisense oligonucleotides
Naoki Iwamoto et al.
NATURE BIOTECHNOLOGY (2017)
LRRK2 Antisense Oligonucleotides Ameliorate α-Synuclein Inclusion Formation in a Parkinson's Disease Mouse Model
Hien Tran Zhao et al.
MOLECULAR THERAPY-NUCLEIC ACIDS (2017)
Gain of Toxicity from ALS/FTD-Linked Repeat Expansions in C9ORF72 Is Alleviated by Antisense Oligonucleotides Targeting GGGGCC-Containing RNAs
Jie Jiang et al.
NEURON (2016)
Huntington disease
Gillian P. Bates et al.
NATURE REVIEWS DISEASE PRIMERS (2015)
Allele-Specific Suppression of Mutant Huntingtin Using Antisense Oligonucleotides: Providing a Therapeutic Option for All Huntington Disease Patients
Niels H. Skotte et al.
PLOS ONE (2014)
Antisense Reduction of Tau in Adult Mice Protects against Seizures
Sarah L. DeVos et al.
JOURNAL OF NEUROSCIENCE (2013)
An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study (vol 12, pg 435, 2013)
T. M. Miller et al.
LANCET NEUROLOGY (2013)
An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study
Timothy M. Miller et al.
LANCET NEUROLOGY (2013)
Sustained Therapeutic Reversal of Huntington's Disease by Transient Repression of Huntingtin Synthesis
Holly B. Kordasiewicz et al.
NEURON (2012)
Share Paper
